

2013 (56)

Alshalalfa Mohammed, Bader Gary D, Bismar Tarek A, Alhadj Reda. Coordinate MicroRNA-Mediated Regulation of Protein Complexes in Prostate Cancer. *PLoS One*. 2013 8 (12) e84261

Chan E, Chan G, Ehrlich L, Hull P, Kreder H, Chu W, Chow E, Emmenegger U. When the tumour is not the culprit: avascular necrosis of the hip in a patient with castration-resistant prostate cancer. *Current Oncology*. 2013 Feb; 20 (1) E48-E51

Cho CF, Azad BB, Luyt LG, Lewis JD. High-Throughput Screening of One-Bead-One-Compound Peptide Libraries Using Intact Cells. *ACS Combinatorial Science*. 2013 Aug; 15 (8) 393-400

Chow Annabelle, Wong Amy, Francia Giulio, Man Shan, Kerbel Robert S, Emmenegger Urban. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. *Investigational New Drugs*. 2013 Feb; 32 47-59

Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. *Clinical Cancer Research*. 2013 Sep; 19 (18) 5202-5209

Daze KD, Hof F. The Cation- π Interaction at Protein-Protein Interaction Interfaces: Developing and Learning from Synthetic Mimics of Proteins That Bind Methylated Lysines. *Accounts of Chemical Research*. 2013 Apr; 46 (4) 937-945

Daze KD, Jones CE, Lilgert BJ, Beshara CS, Hof F. Determining the effects of salt, buffer, and temperature on the complexation of methylated ammonium ions and methyllysines by sulfonated calixarenes. *Canadian Journal of Chemistry*. 2013 Nov; 91 (11) 1072-1076

Djigoué GB, Ngatcha B T, Roy J, Poirier D. Synthesis of 5 α -Androstane-17-spiro- δ -lactones with a 3-Keto, 3-Hydroxy, 3-Spirocarbamate or 3-Spiromorpholinone as Inhibitors of 17 β -Hydroxysteroid Dehydrogenases. *Molecules*. 2013 18 (1) 914-933

Fendler A, Jung M, Stephan C, Erbersdobler A, Jung K, Yousef G. The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. *Clinical Chemistry*. 2013 8 (11) e80807

Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, Qureshi T, Al-Nedawi K. Regulation of the tumor suppressor PTEN through exosomes: A diagnostic potential for prostate cancer. *PLoS One*. 2013 July; 8 e70047

Hamilton TK, Hu NP, Kolomitro K, Bell EN, Maurice DH, Graham CH, Siemens DR. Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. *World Journal of Urology*. 2013 Apr; 31 (2) 325-330

Huang XY, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, Bristow RG, Liu FF, Liu SK. miRNA-95 mediates radioresistance in tumors by targeting the

sphingolipid phosphatase SGPP1. *Cancer Research*. 2013 Dec; 73 (23) 6972-6986

Jin C, McFaul SM, Duffy SP, Deng XY, Tavassoli P, Black PC, Ma HS. Technologies for Label-free Separation of Circulating Tumor Cells: from Historical Foundations to Recent Developments. *Lab on a Chip*. 2013 14 (1) 32-44

Jin Cheng S, Lovell Jonathan F, Chen Juan, Zheng Gang. Ablation of Hypoxic Tumors with Dose-Equivalent Photothermal, but Not Photodynamic, Therapy Using a Nanostructured Porphyrin Assembly. *ACS Nano*. 2013 Mar; 7 2541-2550

Jin Cheng S, Lovell Jonathan F, Zheng Gang. One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles. *Journal of Visualized Experiments*. 2013 Sep; e50536

KC, Al-Mahrouki A, Gorjizadeh A, Karshafian R, Czarnota G. Effects of biophysical parameters in enhancing radiation responses of prostate tumors with ultrasound-stimulated microbubbles. *Ultrasound in Medicine and Biology*. 2013 Aug; 39 (8) 1376-1387-

Klotz L. Active surveillance: patient selection. *Current Opinion in Urology*. 2013 May; 23 (3) 239-244

Lallous N, Dalal K, Cherkasov A, Rennie PS. Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. *International Journal of Molecular Sciences*. 2013 Jun; 14 (6) 12496-12519

Lapi F, Azoulay L, Niazi T, Yin H, Benayoun S, Suissa S. Androgen Deprivation Therapy and Risk of Acute Kidney Injury in Patients With Prostate Cancer. *JAMA*. 2013 July; 310 (3) 289-296

Lévesque Éric, Huang Shu-Pin, Audet-Walsh Étienne, Lacombe Louis, Bao Bo-Ying, Fradet Yves, Laverdière Isabelle, Rouleau Mélanie, Huang Chao-Yuan, Yu Chia-Cheng, Caron Patrick, Guillemette Chantal. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. *Clinical Cancer Research*. 2013 Feb; 19 699-709

Li HF, Hassona MDH, Lack NA, Axerio-Cilies P, Leblanc E, Tavassoli P, Kanaan N, Frewin K, Singh K, Adomat H, Bohm KJ, Prinz H, Guns ET, Rennie PS, Cherkasov A. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer. *Molecular Cancer Therapeutics*. 2013 Nov; 12 (11) 2425-2435

Li HF, Ren X, Leblanc E, Frewin K, Rennie PS, Cherkasov A. Identification of novel androgen receptor antagonists using structure – and ligand-based methods. *Journal of Chemical Information and Modeling*. 2013 Jan; 53 (1) 123-130

Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, Kupchak P, Dharsee M, Nuin PS, Evans KR, Jung K, Stephan C, Fleshner NE, Yousef GM. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. *Clinical Chemistry*. 2013 Nov; 59 (11) 1595-1603

Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: A

systematic literature analysis. *European Journal of Cancer*. 2013 Nov; 49 (16) 3387-3395

Lin BK, McFaul SM, Jin C, Black PC, Ma HS. Highly selective biomechanical separation of cancer cells from leukocytes using microfluidic ratchets and hydrodynamic concentrator. *Biomicrofluidics*. 2013 May; 7 34114

Lin D, Gout PW, Wang YZ. Lessons from in-vivo models of castration-resistant prostate cancer. *Current Opinion in Urology*. 2013 May; 23 (3) 214-219

Liu Liangliang, Li Yunqing, Xie Ning, Shynlova Oksana, Challis John R G, Slater Donna, Lye Stephen, Dong Xuesen. Proliferative action of the androgen receptor in human uterine myometrial cells--a key regulator for myometrium phenotype programming. *Journal of Clinical Endocrinology and Metabolism*. 2013 Jan; 98 218-227

Liu TW, MacDonald TD, Jin CS, Gold JM, Bristow RG, Wilson BC, Zheng G. Inherently Multimodal Nanoparticle-Driven Tracking and Real-Time Delineation of Orthotopic Prostate Tumors and Micrometastases. *ACS Nano*. 2013 May; 7 (5) 4221-4232

Matsumoto Hiroaki, Yamamoto Yoshiaki, Shiota Masaki, Kuruma Hidetoshi, Beraldi Eliana, Matsuyama Hideyasu, Zoubeidi Amina, Gleave Martin. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. *Cancer Research*. 2013 Aug; 73 (16) 5206-5217-

Menard V, Levesque E, Chen S, Eap O, Joy MS, Ekstrom L, Rane A, Guillemette C. Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer. *Pharmacogenetics and Genomics*. 2013 Dec; 23 (12) 684-696

Moiseeva O, Deschenes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN, Ferbeyre G. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF- κ B activation. *Aging Cell*. 2013 Jun; 12 (3) 489-498

Moiseeva Olga, Deschênes-Simard Xavier, Pollak Michael, Ferbeyre Gerardo. Metformin, aging and cancer. *Aging*. 2013 May; 5 330-331

Mosquera Juan Miguel, Beltran Himisha, Park Kyung, MacDonald Theresa Y, Robinson Brian D, Tagawa Scott T, Perner Sven, Bismar Tarek A, Erbersdobler Andreas, Dhir Rajiv, Nelson Joel B, Nanus David M, Rubin Mark A. Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal Treatment-Related Neuroendocrine Prostate Cancer. *Neoplasia*. 2013 Jan; 15 43009

Munuganti RSN, Leblanc E, Axerio-Cilies P, Labriere C, Frewin K, Singh K, Hassona MDH, Lack NA, Li HF, Ban FQ, Guns ET, Young R, Rennie PS, Cherkasov A. Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. Development of 2-((2-phenoxyethyl)thio)-1H-benzimidazole derivatives. *Journal of Medicinal Chemistry*. 2013 Feb; 56 (3) 1136-1148

Nguyen AHT, Tremblay M, Haigh K, Koumakpayi IH, Paquet M, Pandolfi PP, Mes-Masson AM, Saad F, Haigh JJ, Bouchard M. GATA3 antagonizes cancer progression in PTEN-deficient prostates. *Human Molecular Genetics*. 2013 Jun; 22 (12) 2400-2410

Paschos A, Pandya R, Duivenvoorden W C M, Pinthus JH. Oxidative stress in prostate cancer: Changing research concepts towards a novel paradigm for prevention and therapeutics. *Prostate Cancer and Prostatic Diseases*. 2013 Sep; 16 217-225

Pouliot F, Sato M, Jiang ZK, Huyn S, Karanikolas BDW, Wu LL. A Molecular Imaging System Based on Both Transcriptional and Genomic Amplification to Detect Prostate Cancer Cells In Vivo. *Molecular Therapy*. 2013 Mar; 21 (3) 554-560

Qabaja A, Alshalalfa M, Bismar T, Alhadj R. Protein network-based Lasso regression model for the construction of disease-miRNA functional interactions. *EURASIP Journal on Bioinformatics and Systems Biology*. 2013 2013 (1) 3

Rocha J, Zouanat FZ, Zoubeidi A, Hamel L, Benidir T, Scarlata E, Brimo F, Aprikian A, Chevalier S. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. *Molecular and Cellular Endocrinology*. 2013 Dec; 381 140-149

Roy J, Lefebvre J, Maltais R, Poirier D. Inhibition of dehydroepiandrosterone sulfate action in androgen-sensitive tissues by EM-1913, an inhibitor of steroid sulfatase. *Molecular and Cellular Endocrinology*. 2013 Aug; 376 148-155

Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef G, Scorilas A, Diamandis E, Dorn J. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. *Radiology and Oncology*. 2013 47 (4) 319-329

Shiota Masaki, Bishop Jennifer L, Nip Ka Mun, Zardan Anousheh, Takeuchi Ario, Cordonnier Thomas, Beraldi Eliana, Bazov Jenny, Fazli Ladan, Chi Kim, Gleave Martin, Zoubeidi Amina. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. *Cancer Research*. 2013 May; 73 3109-3119

Shukla S, Ablack AL, Wen AM, Lee KL, Lewis JD, Steinmetz NF. Increased Tumor Homing and Tissue Penetration of the Filamentous Plant Viral Nanoparticle Potato virus X. *Molecular Pharmaceutics*. 2013 Jan; 10 (1) 33-42

Tabet S, Douglas SF, Daze KD, Garnett GAE, Allen KJH, Abrioux EMM, Quon TTH, Wulff JE, Hof F. Synthetic trimethyllysine receptors that bind histone 3, trimethyllysine 27 (H3K27me3) and disrupt its interaction with the epigenetic reader protein CBX7. *Bioorganic and Medicinal Chemistry*. 2013 Nov; 21 (22) 7004-7010

Taiakina D, Dal Pra A, Bristow RG. Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. *Advances in Experimental Medicine and Biology*. 2013; 772 189-204

Teng H, Wang C, Dolph M, Donnelly B, Bismar T. ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer. *Urology*. 2013; 2013 786545

Teng LH, Wang C, Begin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. *Urology*. 2013 Aug; 82 (2) 394-399

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, KS, Thaper D, Gleave ME, Zoubeidi A. Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo. *Molecular Cancer Therapeutics*. 2013 Nov; 12 (11) 2342-2355

Toukh M, Siemens DR, Black A, Robb S, Leveridge M, Graham CH, Othman M. Thromboelastography Identifies Hypercoagulability and Predicts Thromboembolic Complications in Patients with Prostate Cancer.. *Thrombosis Research*. 2013 Jan; 133 (1) 88-95

Tran E, Chow A, Goda T, Wong A, Blakely K, Rocha M, Taeb S, Hoang VC, Liu SK, Emmenegger U. Context-dependent role of ATG4B as target for autophagy inhibition in prostate cancer therapy. *Biochemical and Biophysical Research Communications*. 2013 Nov; 441 (4) 726-731

Trudel Dominique, Zafarana Gaetano, Sykes Jenna, Have Cherry L, Bristow Robert G, van der Kwast Theo. 4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. *Journal of Histochemistry and Cytochemistry*. 2013 July; 61 500-509

Wyatt AW, Collins CC. In brief: chromothripsis and cancer. *Journal of Pathology*. 2013 Sep; 231 (1) 1-3

Wyatt AW, Mo F, Wang YZ, Collins CC. The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. *Asian Journal of Andrology*. 2013 May; 15 (3) 301-308

Yan J, Wong N, Hung C, Chen WXY, Tang DM. Contactin-1 Reduces E-Cadherin Expression Via Activating AKT in Lung Cancer. *PLoS One*. 2013 May; 8 e65463

Yu Y, Liu LL, Xie N, Xue H, Fazli L, Buttyan R, Wang YZ, Gleave M, Dong XS. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. *Journal of Clinical Endocrinology and Metabolism*. 2013 July; 98 (7) 2887-2896

Zlotta Alexandre R, Egawa Shin, Pushkar Dmitry, Govorov Alexander, Kimura Takahiro, Kido Masahito, Takahashi Hiroyuki, Kuk Cynthia, Kovylyna Marta, Aldaoud Najla, Fleshner Neil, Finelli Antonio, Klotz Laurence, Sykes Jenna, Lockwood Gina, van der Kwast Theodorus H. Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. *Journal of the National Cancer Institute*. 2013 July; 105 1050-1058